Systemic insulin resistance produces a proatherogenic lipid phenotype Clay F. Semenkovich. J. Clin. Invest. 2006 116:1813-22
Summary of beneficial interventions in insulin resistance Clay F. Semenkovich. J. Clin. Invest. 2006 116:1813-22
Summary of trials using PPAR activation Clay F. Semenkovich. J. Clin. Invest. 2006 116:1813-22
Nutrient excess, organelle stress, and the development of atherosclerosis and insulin resistance Clay F. Semenkovich. J. Clin. Invest. 2006 116:1813-22
DNA damage disorders associated with insulin resistance and atherosclerosis Clay F. Semenkovich. J. Clin. Invest. 2006 116:1813-22